Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study

Costa Clemens, SA; Jepson, B; Bhorat, QE; Ahmad, A; Akhund, T; Aley, PK; Bansal, H; Bibi, S; Kelly, EJ; Khan, M; Lambe, T; Lombaard, JJ; Matthews, S; Pipolo Milan, E; Olsson, U; Ramasamy, MN; Moura de Oliveira Paiva, MS; Seegobin, S; Shoemaker, K; Szylak, A; Villafana, T; Pollard, AJ; Green, JA

COVID-19 Collection

Journal article

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study

Abstract:: Background
AZD2816 is a variant-adapted COVID-19 vaccine that expresses the full-length SARS-CoV-2 beta variant spike protein but is otherwise similar to AZD1222 (ChAdOx1 nCoV-19). This study aimed to evaluate the safety and immunogenicity of AZD1222 or AZD2816 (or both) primary-series vaccination in a cohort of adult participants who were previously unvaccinated.
Methods
In this phase 2/3, randomised, multinational, active-controlled, non-inferiority, immunob... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Costa Clemens, S. A., Jepson, B., Bhorat, Q. E., Ahmad, A., Akhund, T., Aley, P. K., Bansal, H., Bibi, S., Kelly, E. J., Khan, M., Lambe, T., Lombaard, J. J., Matthews, S., Pipolo Milan, E., Olsson, U., Ramasamy, M. N., Moura de Oliveira Paiva, M. S., Seegobin, S., Shoemaker, K., … Green, J. A. (2024). Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study. Lancet Microbe, 5(8).

MLA Style

Costa Clemens, SA, et al. “Immunogenicity and Safety of Beta Variant COVID-19 Vaccine AZD2816 and AZD1222 (ChAdOx1 NCoV-19) as Primary-Series Vaccination for Previously Unvaccinated Adults in Brazil, South Africa, Poland, and the UK: a Randomised, Partly Double-Blinded, Phase 2/3 Non-Inferiority Immunobridging Study.” Lancet Microbe, vol. 5, no. 8, 2024.

Chicago Style

Costa Clemens, SA, B Jepson, QE Bhorat, et al. 2024. “Immunogenicity and Safety of Beta Variant COVID-19 Vaccine AZD2816 and AZD1222 (ChAdOx1 NCoV-19) as Primary-Series Vaccination for Previously Unvaccinated Adults in Brazil, South Africa, Poland, and the UK: a Randomised, Partly Double-Blinded, Phase 2/3 Non-Inferiority Immunobridging Study.” Lancet Microbe 5 (8).
Print